DELIVEREX Trademark

Trademark Overview


On Friday, January 31, 2020, a trademark application was filed for DELIVEREX with the United States Patent and Trademark Office. The USPTO has given the DELIVEREX trademark a serial number of 79282940. The federal status of this trademark filing is REGISTERED as of Tuesday, July 6, 2021. This trademark is owned by Evox Therapeutics Limited. The DELIVEREX trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neu...

Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical scre...
deliverex

General Information


Serial Number79282940
Word MarkDELIVEREX
Filing DateFriday, January 31, 2020
Status700 - REGISTERED
Status DateTuesday, July 6, 2021
Registration Number6405652
Registration DateTuesday, July 6, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 20, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; Medicine for treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; mixed biological preparations for the prevention and treatment of infectious diseases; EV-based nucleic acid therapeutics in the nature of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars, and therapeutics for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strains and tears, ligament strains and tears, muscle atrophy, and muscular dystrophy
Goods and ServicesMedical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy
Pseudo MarkDELIVER EX

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 13, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 13, 2020
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEvox Therapeutics Limited
Party Type30 - Original Registrant
Legal Entity Type24 - NOT AVAILABLE
AddressGB

Party NameEvox Therapeutics Limited
Party Type20 - Owner at Publication
Legal Entity Type24 - NOT AVAILABLE
AddressGB

Party NameEvox Therapeutics Limited
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressGB

Trademark Events


Event DateEvent Description
Saturday, December 4, 2021NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, November 23, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, November 1, 2021FINAL DISPOSITION NOTICE SENT TO IB
Monday, November 1, 2021FINAL DISPOSITION PROCESSED
Wednesday, October 6, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, July 6, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, May 4, 2021LIMITATION FROM THE IB EXAMINED AND ENTERED
Saturday, May 1, 2021LIMITATION OF GOODS RECEIVED FROM IB
Tuesday, April 20, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 20, 2021PUBLISHED FOR OPPOSITION
Sunday, April 18, 2021NOTIFICATION PROCESSED BY IB
Wednesday, March 31, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 31, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, March 31, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, March 13, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 13, 2021EXAMINER'S AMENDMENT ENTERED
Saturday, March 13, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Saturday, March 13, 2021EXAMINERS AMENDMENT E-MAILED
Saturday, March 13, 2021EXAMINERS AMENDMENT -WRITTEN
Saturday, March 6, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Saturday, March 6, 2021LETTER OF SUSPENSION E-MAILED
Saturday, March 6, 2021SUSPENSION LETTER WRITTEN
Thursday, January 28, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 28, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 27, 2021ASSIGNED TO LIE
Friday, October 16, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 30, 2020NEW REPRESENTATIVE AT IB RECEIVED
Friday, May 29, 2020REFUSAL PROCESSED BY IB
Thursday, May 14, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, May 14, 2020REFUSAL PROCESSED BY MPU
Thursday, April 30, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, April 29, 2020NON-FINAL ACTION WRITTEN
Monday, April 20, 2020ASSIGNED TO EXAMINER
Friday, April 17, 2020APPLICATION FILING RECEIPT MAILED
Monday, April 13, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 9, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB